The Science Core B will support activities in all four projects of this IPCAVD Proposal. Core B will be responsible for the production of protein reagents and vaccine immunogens that will be used in Projects One, Two, and Three. Core B will be responsible for the production of recombinant Envelope proteins for analytical studies in Project One, and the production of the Envelope-based immunogens that will be used in for pre-clinical vaccine studies in Project Two. Additionally, Core B will assist in the development of stable protein production cell lines and analytical validation of stably-produced Envelope immunogens in Project Three.

Public Health Relevance

Identifying immunogens and immunization protocols for the optimal stimulation of 'VRCOI-class'germline B cell receptors is one key first step toward generating broadly neutralizing antibodies against HIV by vaccination, and is crucial for the development of an effective vaccine against this virus. The studies in this proposal aim at developing Envelope immunogens that are optimized to engage and stimulate germline 'VRC01'class BCRs and to begin the first steps toward the development of broadly neutralizing activity, and eventually protection from infection with HIV-1. Thus, the activities in this proposal are highly relevant to the development of a universally effective HIV-1 vaccine.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
1U19AI109632-01
Application #
8649610
Study Section
Special Emphasis Panel (ZAI1-NVM-A (S1))
Project Start
Project End
Budget Start
2014-03-05
Budget End
2015-02-28
Support Year
1
Fiscal Year
2014
Total Cost
$220,053
Indirect Cost
$65,841
Name
Seattle Biomedical Research Institute
Department
Type
DUNS #
070967955
City
Seattle
State
WA
Country
United States
Zip Code
98109
McGuire, Andrew T; Dreyer, Anita M; Carbonetti, Sara et al. (2014) HIV antibodies. Antigen modification regulates competition of broad and narrow neutralizing HIV antibodies. Science 346:1380-3